icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
 
 
 
Resistance Analysis of Virologic Failures in Hepatitis C Genotype 1-Infected
Patients Treated With Grazoprevir + Elbasvir ± Ribavirin: the C-WORTHY Study

 
 
  Reported by Jules Levin EASL 2015 April 22-26 Vienna Austria
 
Stuart Black1; Irene Pak1; Paul Ingravallo1; Pat McMonagle1; Robert Chase1; Melissa Shaughnessy1; Peggy Hwang1; Barbara Haber1; P. Richard Harrigan2; Chanson Brumme2; Daria Hazuda1; Anita Y.M. Howe1 1Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA; 2BC Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, Canada
 
MK8408 is a 2nd generation picomolar pangenotypic MS5A inhibitor in development by Merck, and as previously mentioned acquired 2 two nucleotide prodrugs/nuk polymerase inhibitors from Idenix (IDX21437 and IDX21459):
 
A Phase 1 Study to Evaluate the Interaction of HCV NS5B Inhibitor MK-3682 With HCV NS3/4A Protease Inhibitor MK-5172 and HCV NS5A Inhibitor MK-8408 in Healthy Subjects - (04/23/15)
 
MK-8408, a Potent and Selective NS5A Inhibitor With a High Genetic Barrier to Resistance and Activity Against HCV Genotypes 1-6......
http://www.natap.org/2014/AASLD/AASLD_40.htm
 
The Combination of Grazoprevir (MK-5172), an NS3 Inhibitor, and MK-8408, an NS5A Inhibitor, Presents a High Genetic Barrier to Resistance in HCV Genotypes 1a and 3a......http://www.natap.org/2014/AASLD/AASLD_56.htm

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif